Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
190 Leser
Artikel bewerten:
(1)

Tracelink, Inc.: TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation

Finanznachrichten News

TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications

BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored to be named to the Pharmacy500 list for the second year in a row, recognizing 500 organizations that have made a significant impact on the U.S. pharmacy industry over the past year.


"As regulations like the Drug Supply Chain Security Act (DSCSA) reshape the industry, our focus remains on empowering our customers with transformative solutions that ensure compliance, enhance safety, and drive operational excellence," said Shabbir Dahod, President and CEO of TraceLink. "This recognition reflects the trust that our growing digital network community places in TraceLink to help navigate the complexities of the modern supply chain while delivering impactful results to patients."

TraceLink specializes in a comprehensive suite of platform services that address key challenges in the pharmaceutical industry, including DSCSA compliance, track-and-trace orchestration, pharmacy and supply chain inventory visibility, and targeted product recall identification. Furthermore, with the recent launch of OPUS, the Orchestration Platform for Universal Solutions, democratized access to end-to-end supply chain integration and orchestration is finally available for customers and trading partners that wish to propel their supply chain management function to new heights of innovation and efficiency.

Gregory Cianfarani, RPh, Founder and CEO of RXinsider, established the Pharmacy500 to honor companies and organizations that are making a meaningful impact on the pharmaceutical industry. According to Cianfarani, the award "celebrates those companies that are transforming the pharmacy landscape - whether by driving operational efficiencies or advancing exceptional patient care."

In 2024, TraceLink welcomed more than 75 new pharmacy logos to its network, bringing the total number of pharmacy customers to more than 410. This growth reflects a strong demand for TraceLink's innovative solutions, which are helping pharmacies streamline operations and ensure compliance in an increasingly complex regulatory environment. This impressive expansion showcases the widespread adoption of TraceLink's solutions, as customers in the pharmaceutical supply chain industry continue to turn to the platform to enhance efficiency and navigate the evolving regulatory landscape.

With the Magnum release of the OPUS platform earlier this year, TraceLink set a new standard for compliance, supply chain integrity, and process optimization. This milestone innovation solidified TraceLink's position as a leader in the industry, earning its well-deserved recognition among the top organizations driving transformation in the pharmacy supply chain.

To learn more about TraceLink solutions, visit: https://www.tracelink.com/.

About Rxinsider:
Headquartered in West Warwick, Rhode Island, RXinsider is a pharmacist-founded marketing/communications (MARCOM) and market intelligence (INTEL) company focused on pharmacy operations and the companies supporting dispensing pharmacies. Through our publications, digital platforms, market research, and training resources, RXinsider educates pharmacy management and industry professionals on the products, services, and trends that impact pharmacy operations across the supply chain.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.

Logo - https://mma.prnewswire.com/media/1004729/TraceLink_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tracelink-named-to-the-2025-rxinsider-pharmacy500-list-for-excellence-in-pharmacy-supply-chain-innovation-302356574.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.